U.S. Clinical Trials Market Size, Share & Trend Analysis Forecasts 2021 - 2028: Shift Towards Personalized Medicine and Increasing Collaboration in Biomedical Research

Key Facts

DUBLIN--()--The "U.S. Clinical Trials Market Size, Share & Trend Analysis Report By Phase (Phase I, II, III, IV), Study Design (Interventional, Observational), By Indication (Oncology, Diabetes), And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
Clinical Trials Market Size, Share & Trend Analysis Report By Phase (Phase I, II, III, IV), Study Design (Interventional, Observational), By Indication (Oncology, Diabetes), And Segment Forecasts, 2021 - 2028” > > Tweet this The U.S. clinical trials market size is expected to reach USD 32.4 billion by 2028, registering a CAGR of 5.3% over the forecast period.
Clinical Trials: Market Share Analysis, 2020 & 2028 4.2 Phase I 4.3 Phase II 4.4 Phase III 4.5 Phase IV Chapter 5 U.S.
Clinical Trials Indication Outlook, by Study Design, Criss-Cross Analysis Chapter 8 Company Profiles IQVIA Holdings Inc. PAREXEL International Corporation Pharmaceutical Product Development (PPD) Charles River Laboratory ICON plc PRA Health Sciences Syneos Health Inc. SGS SA Wuxi AppTec Eli Lilly and Company Novo Nordisk A/S Pfizer Inc. Covance Inc. Clinipace For more information about this report visit https://www.researchandmarkets.com/r/9mk2gn About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data.